



Express Mail Nos. EM180791039US

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				Application Number	10/575,753
				Filing Date	January 3, 2007
				First Named Inventor	Martin Widschwendter
				Art Unit	1645
				Examiner Name	Not yet assigned
Sheet	1	of	4	Attorney Docket Number	47675-183

U.S. PATENT DOCUMENTS						
Examine r Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Number-Kind Code <sup>4</sup> (if known)				
		US- 5744305	04-28-1998	Fodor		
		US- 5786146	07-28-1998	Herman		
		US- 5837832	11-17-1998	Chee		
		US- 6265171	07-24-2001	Herman		
		US- 6331393	12-18-2001	Laird		

FOREIGN PATENT DOCUMENTS						
Examine r Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
		DE 10348407.8	10-17-2003	Epigenomics AG		
		WO 95/00669	01-05-1995	Pharmacia Biotech AB		
		WO 95/15373	06-08-1995	McGill University		
		WO 97/45560	12-04-1997	North Shore University Hospital Research Corp.		
		WO 97/46705	12-11-1997	Johns Hopkins University School of Medicine		
		WO 99/28498	06-10-1999	Epigenomics GMBH		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		ALTSCHUL et al., "Basic Local Alignment Search Tool," Journal of Molecular Biology, 1990, pp. 403-410, Volume 215	
		ALTSCHUL et al., "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs," Nucleic Acids Research, 1997, pp. 3389-3402, Volume 25	
		ALTSCHUL, "A Protein Alignment Scoring System Sensitive at All Evolutionary Distances," Journal of Molecular Evolution, 1993, pp. 290-300, Volume 36	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04 <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Express Mail Nos. EM180791039US

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Sheet	2	of	4	Application Number	10/575,753
				Filing Date	January 3, 2007
				First Named Inventor	Martin Widschwendter
				Art Unit	1645
				Examiner Name	Not yet assigned
				Attorney Docket Number	47675-183

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		ANKER et al., "Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients," Cancer and Metastasis Reviews, 1999, pp. 65-73, Volume 18	
		BASELGA et al., "Focus on breast cancer," Cancer Cell, 2002, pp. 319-322, Volume 1	
		BRUTLAG et al., "Improved sensitivity of biological sequence database searches," Computer Applications in the Biosciences, 1990, pp. 237-245, Volume 6	
		COOMBES et al., "A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer," The New England Journal of Medicine, 2004, pp. 1081-1092, Volume 350	
		DAMMANN et al., "Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3," Nature Genetics, 2000, pp. 315-319, Volume 25	
		DAMMANN et al., "Epigenetic inactivation of the Ras-association domain family 1 (RASSF1A) gene and its function in human carcinogenesis," Histology and Histopathology, 2003, pp. 665-677, Volume 18	
		DAMMANN et al., "Hypermethylation of the CpG Island of Ras Association Domain Family 1A (RASSF1A), a Putative Tumor Suppressor Gene from the 3p21.3 Locus, Occurs in a Large Percentage of Human Breast Cancers," Cancer Research, 2001, pp. 3105-3109, Volume 61	
		EADS et al., "Epigenetic Patterns in the Progression of Esophageal Adenocarcinoma," Cancer Research, April 15, 2001, pp. 3410-3418, Volume 61	
		EADS et al., "MethylLight: a high-throughput assay to measure DNA methylation," Nucleic Acids Research, 2000, p. e32, Volume 28 (8 pages)	
		EARLY BREAST CANCER TRIALISTS' COLLABORATIVE GROUP, "Tamoxifen for early breast cancer: an overview of randomised trials," The Lancet, 1998, pp. 1451-1467, Volume 351	
		FEARNHEAD et al., "The ABC of APC," Human Molecular Genetics, 2001, pp. 721-733, Volume 10	
		FEIL et al., "Methylation analysis on individual chromosomes: improved protocol for bisulphite genomic sequencing," Nucleic Acids Research, 1994, pp. 695-696, Volume 22	
		FRAGA et al., "DNA Methylation: A Profile of Methods and Applications," BioTechniques, 2002, pp. 632-649, Volume 33	
		GOLDHIRSCH et al., "Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer," Journal of Clinical Oncology, 2001, pp. 3817-3827, Volume 19	
		GONZALGO et al., "Rapid quantitation of methylation differences at specific sites using methylation-sensitive single nucleotide primer extension (Ms-SNuPE), Nucleic Acids Research, 1997, pp. 2529-2531, Volume 25	
		GOSS et al., "A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer," The New England Journal of Medicine, 2003, pp. 1793-1802, Volume 349	

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04 <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

DWT 12262777v1 0047675-000183



Express Mail Nos. EM180791039US

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>		Application Number	10/575,753		
		Filing Date	January 3, 2007		
		First Named Inventor	Martin Widschwendter		
		Art Unit	1645		
		Examiner Name	Not yet assigned		
Sheet	3	of	4	Attorney Docket Number	47675-183

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		GRIGG et al., "Sequencing 5-Methylcytosine Residues in Genomic DNA," BioEssays, June 1994, pp. 431-436, Volume 16	
		GUT et al., "DNA and Matrix Assisted Laser Desorption Ionization Mass Spectrometry," Molecular Biology: Current Innovations and Future Trends, 1995, pp. 147-157, Horizon Scientific Press, Wymondham, United Kingdom	
		GUT et al., "A procedure for selection DNA alkylation and detection by mass spectrometry," Nucleic Acids Research, 1995, pp. 1367-1373, Volume 23	
		HEID et al., "Real Time Quantitative PCR," Genome Research, 1996, pp. 986-994, Volume 6	
		HERMAN et al., "Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands," The Proceedings of the National Academy of Sciences, 1996, pp. 9821-9826, Volume 93	
		JONES et al., "The Fundamental Role of Epigenetic Events in Cancer," Nature Reviews/Genetics, 2002, pp. 415-428, Volume 3	
		KARAS et al., "Laser Desorption Ionization of Proteins with Molecular Masses Exceeding 10 000 Daltons," Analytical Chemistry, October 15, 1988, pp. 2299-2301, Volume 60	
		KAWAKAMI et al., "Hypermethylated APC DNA in Plasma and Prognosis of Patients With Esophageal Adenocarcinoma," Journal of the National Cancer Institute, 2000, pp. 1805-1811, Volume 92	
		KLEIN et al., "Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer," The Lancet, 2002, pp. 683-689, Volume 360	
		LECOMTE et al., "Detection of Free-Circulating Tumor-Associated DNA in Plasma of Colorectal Cancer Patients and Its Association with Prognosis," International Journal of Cancer, 2002, pp. 542-548, Volume 100	
		LEON et al., "Free DNA in the Serum of Cancer Patients and the Effect of Therapy," Cancer Research, 1977, pp. 646-650, Volume 37	
		MARTIN et al., "Genomic sequencing indicates a correlation between DNA hypomethylation in the 5' region on the pS2 gene and its expression in human breast cancer cell lines," Gene, 1995, pp. 261-264, Volume 157	
		MÜLLER et al., "DNA Methylation in Serum of Breast Cancer Patients: An Independent Prognostic Marker," Cancer Research, 2003, pp. 7641-7645, Volume 63	
		OLEK et al., "A modified and improved method for bisulphite based cytosine methylation analysis," Nucleic Acids Research, 1996, pp. 5064-5066, Volume 24	
		OLEK et al., "The pre-implantation ontogeny of the H19 methylation imprint," Nature Genetics, November 1997, pp. 275-276, Volume 17	
		RIGGS et al., "Selective Estrogen-Receptor Modulators - Mechanisms of Action and Application to Clinical Practice," The New England Journal of Medicine, 2003, pp. 618-629, Volume 348	
		SANGER et al., "DNA sequencing with chain-terminating inhibitors," PNAS, December 1977, pp. 5463-5467, Volume 74	

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04 <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

DWT 1226277v1 0047675-000183



Express Mail Nos.EM180791039US

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>		Application Number	10/575,753
		Filing Date	January 3, 2007
		First Named Inventor	Martin Widschwendter
		Art Unit	1645
		Examiner Name	Not yet assigned
		Attorney Docket Number	47675-183
Sheet	4	of	4

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		SHAO et al., "p53 Mutation in Plasma DNA and Its Prognostic Value in Breast Cancer Patients," Clinical Cancer Research, 2001, pp. 2222-2227, Volume 7	
		SILVA et al., "Persistence of Tumor DNA in Plasma of Breast Cancer Patients After Mastectomy," The Annals of Surgical Oncology, 2002, p-p. 72-76, Volume 9	
		SILVA et al., "Presence of Tumor DNA in Plasma of Breast Cancer Patients: Clinicopathological Correlations," Cancer Research, 1999, pp. 3251-3256, Volume 59	
		SONG et al., "The tumour suppressor RASSF1A regulates mitosis by inhibiting the APC-Cdc20 complex," Nature Cell Biology, 2004, pp. 129-137, Volume 6	
		THOMPSON et al., "CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice," Nucleic Acids Research, 1994, pp. 4673-4680, Volume 22	
		VAN DE VIJVER, "A Gene-Expression Signature As A Predictor Of Survival In Breast Cancer," The New England Journal of Medicine, 2002, pp. 1999-2009, Volume 347	
		VAN 'T VEER et al., "Gene expression profiling predicts clinical outcome of breast cancer," Nature, January 31, 2002, pp. 530-536, Volume 415	
		VIRMANI et al., "Aberrant Methylation of the Adenomatous Polyposis Coli (APC) Gene Promoter 1A in Breast and Lung Carcinomas," Clinical Cancer Research, 2001, pp. 1998-2004, Volume 7	
		WIDSCHWENDTER et al., "DNA methylation and breast carcinogenesis," Oncogene, 2002, pp. 5462-5482, Volume 21	
		WONG et al., "Detection of Aberrant p16 Methylation in the Plasma and Serum of Liver Cancer Patients," Cancer Research, 1999, pp. 71-73, Volume 59	
		XIONG et al., "COBRA: a sensitive and quantitative DNA methylation assay," Nucleic Acids Research, 1997, pp. 2532-2534, Volume 25	
		YU et al., "Specific Inhibition of PCR by Non-Extendable Oligonucleotides Using a 5' to 3' Exonuclease-Deficient DNA Polymerase," BioTechniques, October 1997, pp. 714-720, Volume 23	
		ZESCHNIGK et al., "Imprinted segments in the human genome: different DNA methylation patterns in the Prader-Willi/Angelman syndrome region as determined by the genomic sequencing method," Human Molecular Genetics, 1997, pp. 387-395, Volume 6	
		ZESCHNIGK et al., "A single-tube PCR test for the diagnosis of Angelman and Prader-Willi syndrome based on allelic methylation differences at the SNRPN locus," European Journal of Human Genetics, March-April 1997, pp. 94-98, Volume 5	

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04 <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard St.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

DWT 12262777v1 0047675-000183